Monday, September 26, 2011

Farmacopea de los Estados Unidos Mexicanos - FEUM : Suplemento para Dispositivos Médicos, Segunda Edición, 2011, ISBN: 978-607-460-189-3

El actual enfoque de riesgo sanitario bajo el cual han sido observados los dispositivos médicos los ha posicionado ya no como coadyuvantes en los tratamientos para la prevención, diagnóstico y rehabilitación de las enfermedades, sino en un lugar protagónico en el cuidado de la salud, principalmente por la existencia de padecimientos que los “medicamentos no pueden curar” como es el caso de la hidrocefalia o de algunos problemas cardiacos.

El presente suplemento de la Farmacopea Mexicana especializado en dispositivos médicos, se ha diseñado para asegurar que estos insumos para la salud puedan alcanzar un grado óptimo de seguridad y funcionamiento, implementando las pruebas y requisitos para que los productos se ajusten a las normas de calidad exigidas.

Contenido:

- 58 Métodos Generales de Análisis
- 171 Monografías de Dispositivos Médicos

Hace cuatro años, en 2006, se publicó la primera edición del Suplemento de la Farmacopea de los Estados Unidos Mexicanos especializado en dispositivos médicos. Su publicación fue un acontecimiento muy importante ya que en él se vio consolidado el trabajo y la participación activa de muchos integrantes de todos los sectores relevantes en este tema como son los académicos, los industriales, las autoridades y la comunidad de profesionales, que son responsables, cada uno en el ámbito que le corresponde, de que los lineamientos publicados en este Suplemento se apliquen y regule a los campos de la producción, control de la calidad y comercialización de los dispositivos médicos.

En los últimos años la Industria de los dispositivos médicos se ha convertido en una de las más importantes, con un crecimiento en dispositivos innovadores y con avances tecnológicos, éste Suplemento es una herramienta de gran utilidad para los industriales y autoridades de regulación sanitaria nacionales e internacionales que proporciona las reglas claras del proceso de regulación sanitaria y las especificaciones que serán evaluadas para verificar la Calidad, seguridad y eficacia de los Dispositivos Médicos.

Haber publicado el primer suplemento ha sido un logro muy importante, sin embargo, es necesario mantener el nivel de actualización acorde a los avances tecnológicos, de innovación, de fabricación y analíticos, que conlleva a continuos cambios en los marcos regulatorios internacionales. Por esta razón es un motivo más de reconocimiento al trabajo realizado y coordinado por la Comisión Permanente de la Farmacopea de los Estados Unidos Mexicanos, la publicación de la Segunda edición de este Suplemento que permitió la revisión y actualización del material ya existente y ahora consta de un mayor número de monografías y métodos analíticos para dispositivos médicos.

En este Suplemento se definen y establecen las especificaciones que deben cumplir los dispositivos médicos para que tengan la calidad y el nivel de funcionamiento óptimo, así como los métodos de análisis para su verificación. La aplicación de estos métodos de análisis y su cumplimiento son la garantía de la seguridad y eficacia de estos insumos.

Un trabajo de esta magnitud solamente puede ser realizado por un equipo de trabajo multidisciplinario, no sólo interesado, sino comprometido con su profesión, con su entorno social y con su país. Las personas que conforman estos grupos de trabajo son las que nos llevan a alcanzar las metas que nos hemos propuesto en cuestión de los procesos de regulación sanitaria. Gracias a todas ellas y a las instituciones que las respaldan es que tenemos el beneplácito de presentar esta segunda edición del Suplemento de Dispositivos Médicos.

Friday, September 23, 2011

Farmacopea de los Estados Unidos Mexicanos. FEUM ; Décima Edición; 10ª edición - 2011; ( 978-607-460-203-6 )


AVISO REFERENTE A LA VENTA DE LA DECIMA EDICION DE LA FARMACOPEA DE LOS ESTADOS UNIDOS MEXICANOS.

La Farmacopea de los Estados Unidos Mexicanos es el documento instituido por la Ley General de Salud, expedido y reconocido por la Secretaría de Salud, donde se consignan los métodos generales de análisis y los requisitos sobre la identidad, pureza y calidad que garantice que los fármacos, aditivos, medicamentos, productos biológicos y dispositivos médicos sean funcionales, eficaces y seguros, de acuerdo a las características propias del país.

Es de carácter obligatorio para los establecimientos que se dediquen al proceso de los medicamentos y demás insumos para la salud, en los términos del artículo 258 de la Ley General de Salud.

La misión de la Farmacopea de los Estados Unidos Mexicanos es buscar la excelencia de los medicamentos y demás insumos para la salud mediante el establecimiento de los métodos de análisis y las especificaciones de calidad de los mismos. Los profesionales de las ciencias farmacéuticas y médicas, unidos a través de la Comisión Permanente de la Farmacopea de los Estados Unidos Mexicanos, trabajan en forma complementaria, analizando los aspectos clínicos, farmacéuticos y tecnológicos, que tienen impacto en la calidad, eficacia y seguridad de los medicamentos y demás insumos para la salud.

Es por estos motivos que se instituye como norma oficial mexicana el procedimiento a partir del cual se revisa, actualiza, edita y difunde la Farmacopea de los Estados Unidos Mexicanos y sus Suplementos.

Atentamente

Joao Hecker.

Wednesday, September 14, 2011

Publicacoes Internacionais Hecker JF: SA8000 : 2008 Standard *** SA8000® *** Third Issue...

Publicacoes Internacionais Hecker JF: SA8000 : 2008 Standard *** SA8000® *** Third Issue...: The SA8000® standard is the central document of our work at SAI. It is an auditable certification standard based on international workplace ...

SA8000 : 2008 Standard *** SA8000® *** Third Issue *** SAI Social Accountability International

The SA8000® standard is the central document of our work at SAI. It is an auditable certification standard based on international workplace norms of International Labour Organisation (ILO) conventions, the Universal Declaration of Human Rights and the UN Convention on the Rights of the Child. This standard is the benchmark against which companies and factories measure their performance. Those seeking to comply with SA8000® have adopted policies and procedures that protect the basic human rights of workers.

SA8000® Elements

1.  Child Labor: No use or support of child labor; policies and written procedures for remediation of children found to be working in situation; provide adequate financial and other support to enable such children to attend school; and employment of young workers conditional.
2. Forced and Compulsory Labor: No use or support for forced or compulsory labor; no required 'deposits' - financial or otherwise; no withholding salary, benefits, property or documents to force personnel to continue work; personnel right to leave premises after workday; personnel free to terminate their employment; and no use nor support for human trafficking.
3. Health and Safety: Provide a safe and healthy workplace; prevent potential occupational accidents; appoint senior manager to ensure OSH; instruction on OSH for all personnel; system to detect, avoid, respond to risks; record all accidents; provide personal protection equipment and medical attention in event of work-related injury; remove, reduce risks to new and expectant mothers; hygiene- toilet, potable water, sanitary food storage; decent dormitories- clean, safe, meet basic needs; and worker right to remove from imminent danger.
4. Freedom of Association and Right to Collective Bargaining: Respect the right to form and join trade unions and bargain collectively. All personnel are free to: organize trade unions of their choice; and bargain collectively with their employer. A company shall: respect right to organize unions & bargain collectively; not interfere in workers’ organizations or collective bargaining; inform personnel of these rights & freedom from retaliation; where law restricts rights, allow workers freely elect representatives; ensure no discrimination against personnel engaged in worker organizations; and ensure representatives access to workers at the workplace.
5. Discrimination: No discrimination based on race, national or social origin, caste, birth, religion, disability, gender, sexual orientation, union membership, political opinions and age. No discrimination in hiring, remuneration, access to training, promotion, termination, and retirement. No interference with exercise of personnel tenets or practices; prohibition of threatening, abusive, exploitative, coercive behaviour at workplace or company facilities; no pregnancy or virginity tests under any circumstances.
6. Disciplinary Practices: Treat all personnel with dignity and respect; zero tolerance of corporal punishment, mental or physical abuse of personnel; no harsh or inhumane treatment.
7. Working Hours: Compliance with laws & industry standards; normal workweek, not including overtime, shall not exceed 48 hours; 1 day off following every 6 consecutive work days, with some exceptions; overtime is voluntary, not regular, not more than 12 hours per week; required overtime only if negotiated in CBA.
8. Remuneration: Respect right of personnel to living wage; all workers paid at least legal minimum wage; wages sufficient to meet basic needs & provide discretionary income; deductions not for disciplinary purposes, with some exceptions; wages and benefits clearly communicated to workers; paid in convenient manner – cash or check form; overtime paid at premium rate; prohibited use of labor-only contracting, short-term contracts, false apprenticeship schemes to avoid legal obligations to personnel.
9. Management Systems: Facilities seeking to gain and maintain certification must go beyond simple compliance to integrate the standard into their management systems and practices.

Publicacoes Internacionais Hecker JF: IMDG Code 2010 Edition - The IMDG Code (inc Amdt 3...

Publicacoes Internacionais Hecker JF: IMDG Code 2010 Edition - The IMDG Code (inc Amdt 3...: IMDG Code 2010 Edition - incorporating Amendment 35-10 IMO Sales No. IH200E The IMDG Code has undergone many changes over the years, in bo...

IMDG Code 2010 Edition - The IMDG Code (inc Amdt 34-08) is currently in force. The Code as amended by Amendment 35-10 is mandatory as from 1 January 2012 but may be applied by Administrations in whole or in part on a voluntary basis from 1 January 2011.

IMDG Code 2010 Edition - incorporating Amendment 35-10 IMO Sales No. IH200E

The IMDG Code has undergone many changes over the years, in both format and content, in order to keep up with the rapid expansion of the shipping industry. Amendment 35-10 includes revisions to various sections of the Code and to transport requirements for specific substances. It was adopted by IMO’s Maritime Safety Committee (MSC) at its 87th session in May 2010.

The MSC had previously agreed that the Code as it was adopted in 2002 would be mandatory as from 1 January 2004. The Code as amended by Amendment 35-10 is mandatory as from 1 January 2012 but may be applied by Administrations in whole or in part on a voluntary basis from 1 January 2011.The Code as amended by amendment 35-10 is mandatory as from 1 January 2012 but may be applied by Administrations in whole or in part on a voluntary basis from 1 January 2011.

Publicacoes Internacionais Hecker JF: Brazil Oil & Gas Report : Published: 15 Jul 2011 ...

Publicacoes Internacionais Hecker JF: Brazil Oil & Gas Report : Published: 15 Jul 2011 ...: Published: 15 Jul 2011 Quarterly 117 pages Includes 3 FREE quarterly updates PDF delivery via email, hard copies via first-class mail ...

Brazil Oil & Gas Report : Published: 15 Jul 2011 - Quarterly - Includes 3 FREE quarterly updates

Published: 15 Jul 2011 | Quarterly
117 pages
Includes 3 FREE quarterly updates
PDF delivery via email, hard copies via first-class mail

Product DescriptionExecutive Summary
 
The Brazil Oil and Gas Report has been researched at source and features Business Monitor International (BMI)'s independent 5 and 10-year forecasts for Brazil including major indicators for oil, gas and LNG, covering all major indicators including reserves, production, consumption, refining capacity, prices, export volumes and values. The report includes full analysis of industry trends and prospects, multinational and national companies, and changes in the regulatory environment.
BMI's Brazil Oil and Gas Report provides professionals, consultancies, government departments, regulatory bodies and researchers with independent forecasts and competitive intelligence on the Brazilian oil and gas industry.
 
Key Benefits
 
* Benchmark BMI's independent 5 and 10-year oil and gas industry forecast for Brazil to test consensus views - a key input for successful budgeting and strategic business planning in the Brazilian oil and gas market.
* Target business opportunities and risks in the Brazilian oil and gas sector through reviews of latest industry trends, regulatory changes, and major deals, projects and investments in Brazil.
* Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs, latest activity) and Competitive Landscape Tables.
 

 
Summary of BMI's key forecasts and industry analysis, covering oil and gas reserves, supply, demand and refining, plus analysis of landmark company developments and key changes in the regulatory environment.
 
Regional Overview
 
Regional perspective on size and value of industry sector; comparative rankings by production, refining, imports and exports of oil, gas and LNG.
 
Business Environment Ratings
 
BMI's Oil and Gas Business Environment Rating provides a country-comparative risk-reward index aimed at investors - independents, NOCs, IOCs, oil services companies - in the upstream and downstream markets.
The ratings methodology makes sophisticated use of more than 40 industry, economic and demographic data points.
 
Oil Market Outlook and Oil Products Outlook
 
Based on our country coverage of over 99% of global oil and gas production and consumption, BMI provides 5-year demand, supply and price forecasts for oil, gas and oil products.
 
BMI 5 and 10-Year Industry Forecast
 
Historic data series and 5 and 10-year forecasts for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Pricing: Oil price (US$/bbl, WTI, Brent, OPEC basket, Urals); Oil products prices (unleaded gasoline, gasoil/diesel, jet/kerosene - US$bbl) at global hubs
Production, Consumption, Capacity and Reserves: Proven oil reserves (bn barrels), production, consumption, refinery capacity and throughputs (`000b/d); Proven gas reserves (tcm), production and consumption (bcm)
Imports and Exports: Oil exports/imports (`000b/d), value of oil exports/imports (US$mn - BMI base case); Value of oil exports at constant US$50/bbl and constant US$100/bbl (US$mn); Gas exports/imports (bcm), Value of gas exports/imports (US$mn); Value of gas exports/imports at constant US$50/bbl and US$100/bbl (US$mn); Value of petroleum exports/imports (US$mn); Value of petroleum exports/imports at constant US$50/bbl and US$100/bbl (US$mn)
 
BMI 5-Year Macroeconomic Forecast
 
BMI forecasts for all headline macroeconomic indicators, including real GDP growth, inflation, fiscal balance, trade balance, current account and external debt.
 
Competitive Landscape
 
Comparative company analyses and rankings by US$ sales, % share of total sales, number of employees, year established, ownership structure, oil production (`000 b/d) and % market share, downstream capacity (`000 b/d) and % market share.
 
Company Profiles
 
Examining the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT (Strengths, Weaknesses, Opportunities and Threats) analyses. Latest financial and operating statistics and key company developments are also incorporated within our company profiles, enabling a full evaluation of recent company performance and future growth prospects.